Towa Pharmaceutical Co., Ltd.
Notice of Change in Disclosure Item: Change of Share Transfer Execution Date for Acquisition of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Co., Ltd. (Wholly Owned Subsidiarization)
The share transfer execution date has been changed from scheduled end of November 2026 to scheduled end of December 2026. The reason is to carefully confirm the transition process and secure sufficient preparation time. Impact on consolidated earnings guidance for the fiscal year ending March 2027 is minor; negative goodwill is expected to arise.
Key Figures
- Share transfer execution date: Before change end of November 2026 → After change end of December 2026
- Impact: Minor impact on consolidated earnings guidance for the fiscal year ending March 2027
- Goodwill: Negative goodwill expected to arise
AI要約
Details of the Change and Background
Regarding the acquisition of shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Co., Ltd. (wholly owned subsidiarization) and the transfer of marketing authorization, we have decided to change the share transfer execution date to the end of December 2026 (scheduled). The change is to allow both companies to carefully confirm the transition process and ensure a sufficient preparation period.
Outlook and Impact
This change of date is expected to have only a minor impact on the Company’s consolidated earnings guidance for the fiscal year ending March 2027. In addition, negative goodwill is expected to arise as a result of the share acquisition; the amount of goodwill and the impact on earnings guidance will be promptly disclosed once details are finalized.
Towa Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
